The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Covering Every FDA Oncology Approval From October 2025 CURE FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Compounded "semaglutide" is not FDA approved semaglutide.com